UA76396C2 - Monoclonal antibody, which is able to be bound with receptor ifn -, block the biological activity of ifn- and ifn- and create higher antiviral titer against fn-, than against ifn- (variants), pharmaceutical composition for modulation or blocking biological activity of ifn-, hybridoma expressing denoted antibody (variants), and set for carrying out elisa-analysis of ifnab-bpi and/or ifnab-bpi - Google Patents

Monoclonal antibody, which is able to be bound with receptor ifn -, block the biological activity of ifn- and ifn- and create higher antiviral titer against fn-, than against ifn- (variants), pharmaceutical composition for modulation or blocking biological activity of ifn-, hybridoma expressing denoted antibody (variants), and set for carrying out elisa-analysis of ifnab-bpi and/or ifnab-bpi Download PDF

Info

Publication number: UA76396C2
Authority: UA; Ukraine
Prior art keywords: ifn; iem; biological activity; antibody; antibodies
Prior art date: 1996-05-01

Application number

UA98116315A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-01

Filing date

1997-04-29

Publication date

2006-08-15

1997-04-29 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

2006-08-15 Publication of UA76396C2 publication Critical patent/UA76396C2/uk

Links

230000004071 biological effect Effects 0.000 title claims abstract description 20
230000000903 blocking effect Effects 0.000 title claims abstract description 20
230000000840 anti-viral effect Effects 0.000 title claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
210000004408 hybridoma Anatomy 0.000 title claims description 19
238000002965 ELISA Methods 0.000 title abstract 2
241000282414 Homo sapiens Species 0.000 claims abstract description 16
108060003951 Immunoglobulin Proteins 0.000 claims abstract description 6
102000018358 immunoglobulin Human genes 0.000 claims abstract description 6
238000004458 analytical method Methods 0.000 claims description 6
239000011248 coating agent Substances 0.000 claims description 4
238000000576 coating method Methods 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
238000005497 microtitration Methods 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
238000012876 topography Methods 0.000 claims 1
102000014150 Interferons Human genes 0.000 abstract description 5
108010050904 Interferons Proteins 0.000 abstract description 5
208000023275 Autoimmune disease Diseases 0.000 abstract description 4
208000031886 HIV Infections Diseases 0.000 abstract description 4
229940079322 interferon Drugs 0.000 abstract description 4
208000037357 HIV infectious disease Diseases 0.000 abstract description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 3
230000002588 toxic effect Effects 0.000 abstract description 3
241000124008 Mammalia Species 0.000 abstract description 2
206010012601 diabetes mellitus Diseases 0.000 abstract description 2
231100000331 toxic Toxicity 0.000 abstract description 2
238000010348 incorporation Methods 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 description 43
235000018102 proteins Nutrition 0.000 description 37
102000004169 proteins and genes Human genes 0.000 description 37
230000000694 effects Effects 0.000 description 32
210000004027 cell Anatomy 0.000 description 31
238000000034 method Methods 0.000 description 24
102000005962 receptors Human genes 0.000 description 24
108020003175 receptors Proteins 0.000 description 24
108020004414 DNA Proteins 0.000 description 15
150000003839 salts Chemical class 0.000 description 14
239000013598 vector Substances 0.000 description 14
230000027455 binding Effects 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 11
239000000427 antigen Substances 0.000 description 10
102000036639 antigens Human genes 0.000 description 10
108091007433 antigens Proteins 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
235000001014 amino acid Nutrition 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
239000012634 fragment Substances 0.000 description 8
239000013612 plasmid Substances 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
-1 DNA or RNA Chemical class 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
125000000539 amino acid group Chemical group 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 7
239000000243 solution Substances 0.000 description 7
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
210000005260 human cell Anatomy 0.000 description 6
210000003205 muscle Anatomy 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 5
230000004927 fusion Effects 0.000 description 5
230000003053 immunization Effects 0.000 description 5
108020004707 nucleic acids Proteins 0.000 description 5
102000039446 nucleic acids Human genes 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
239000000523 sample Substances 0.000 description 5
102000002227 Interferon Type I Human genes 0.000 description 4
108010014726 Interferon Type I Proteins 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
239000002253 acid Substances 0.000 description 4
210000003567 ascitic fluid Anatomy 0.000 description 4
125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 4
238000009795 derivation Methods 0.000 description 4
230000003472 neutralizing effect Effects 0.000 description 4
241000894007 species Species 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
238000005406 washing Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
235000008733 Citrus aurantifolia Nutrition 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
101710186227 S-adenosylmethionine synthase Proteins 0.000 description 3
102100026115 S-adenosylmethionine synthase isoform type-1 Human genes 0.000 description 3
240000006909 Tilia x europaea Species 0.000 description 3
235000011941 Tilia x europaea Nutrition 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000002649 immunization Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000004571 lime Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
208000017972 multifocal atrial tachycardia Diseases 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
241000711975 Vesicular stomatitis virus Species 0.000 description 2
241000405119 Virga Species 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000003277 amino group Chemical class 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
102000023732 binding proteins Human genes 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000010367 cloning Methods 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
229920000936 Agarose Polymers 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
235000017399 Caesalpinia tinctoria Nutrition 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
241000700626 Cowpox virus Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical class [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
241000545744 Hirudinea Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000001617 Interferon Receptors Human genes 0.000 description 1
108010054267 Interferon Receptors Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
MMVYPOCJESWGTC-UHFFFAOYSA-N Molybdenum(2+) Chemical compound [Mo+2] MMVYPOCJESWGTC-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100380295 Mus musculus Asah1 gene Proteins 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
241000388430 Tara Species 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000003139 biocide Substances 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011575 calcium Chemical class 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000005043 ethylene-methyl acrylate Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229960001388 interferon-beta Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
229910052725 zinc Chemical class 0.000 description 1
239000011701 zinc Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Mycology (AREA)
Diabetes (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Epidemiology (AREA)
Food Science & Technology (AREA)
Obesity (AREA)
Plant Pathology (AREA)

UA98116315A 1996-05-01 1997-04-29 Monoclonal antibody, which is able to be bound with receptor ifn -, block the biological activity of ifn- and ifn- and create higher antiviral titer against fn-, than against ifn- (variants), pharmaceutical composition for modulation or blocking biological activity of ifn-, hybridoma expressing denoted antibody (variants), and set for carrying out elisa-analysis of ifnab-bpi and/or ifnab-bpi UA76396C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL11809696A IL118096A0 (en)	1996-05-01	1996-05-01	Antibodies against interferon alpha/beta receptor
PCT/IL1997/000138 WO1997041229A1 (en)	1996-05-01	1997-04-29	Antibodies against interferon alpha/beta receptor

Publications (1)

Publication Number	Publication Date
UA76396C2 true UA76396C2 (en)	2006-08-15

Family

ID=11068814

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA98116315A UA76396C2 (en)	1996-05-01	1997-04-29	Monoclonal antibody, which is able to be bound with receptor ifn -, block the biological activity of ifn- and ifn- and create higher antiviral titer against fn-, than against ifn- (variants), pharmaceutical composition for modulation or blocking biological activity of ifn-, hybridoma expressing denoted antibody (variants), and set for carrying out elisa-analysis of ifnab-bpi and/or ifnab-bpi

Country Status (19)

Country	Link
US (1)	US6136309A (xx)
EP (2)	EP1739177A1 (xx)
JP (1)	JP4308322B2 (xx)
KR (2)	KR100581798B1 (xx)
CN (1)	CN1198929C (xx)
AT (1)	ATE342981T1 (xx)
AU (1)	AU719995B2 (xx)
BR (1)	BR9709202A (xx)
CA (1)	CA2253239C (xx)
DE (1)	DE69736835T2 (xx)
DK (1)	DK0927252T3 (xx)
EA (1)	EA002543B1 (xx)
ES (1)	ES2274542T3 (xx)
HK (1)	HK1019339A1 (xx)
IL (2)	IL118096A0 (xx)
NO (1)	NO324206B1 (xx)
PT (1)	PT927252E (xx)
UA (1)	UA76396C2 (xx)
WO (1)	WO1997041229A1 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0563487A1 (en) *	1992-03-31	1993-10-06	Laboratoire Europeen De Biotechnologie S.A.	Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US6713609B1 (en)	1996-07-16	2004-03-30	Genentech, Inc.	Monoclonal antibodies to type I interferon receptor
US6376067B1 (en) *	1998-12-21	2002-04-23	Mitsubishi Polyester Film, Llc	Silicone coated film with back side slip control coating and method of controlling slip of such film
RU2181297C2 (ru)	2000-06-20	2002-04-20	Эпштейн Олег Ильич	Способ лечения патологического синдрома и лекарственное средство
ATE502648T1 (de) *	2001-01-09	2011-04-15	Baylor Res Inst	Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
AU2007202840B2 (en) *	2001-01-09	2011-07-28	Baylor Research Institute	Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en)	2001-02-22	2006-08-08	Genentech, Inc.	Anti-interferon-α antibodies
UA76640C2 (uk) *	2002-08-02	2006-08-15	Олєг Ільіч Епштєйн	Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76638C2 (en) *	2002-08-02	2006-08-15	Oleh Illich Epshtein	Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76639C2 (uk) *	2002-08-02	2006-08-15	Олєг Ільіч Епштєйн	Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
WO2004093908A2 (en) *	2003-04-23	2004-11-04	Medarex, Inc.	Compositions and methods for the therapy of inflammatory bowel disease
AU2007203559B2 (en) *	2003-04-23	2010-09-02	E. R. Squibb & Sons, L.L.C.	Compositions and methods for the therapy of inflammatory bowel disease
LT2418220T (lt)	2003-12-10	2017-10-10	E. R. Squibb & Sons, L.L.C.	Interferono-alfa antikūnai ir jų panaudojimas
EP1781705B1 (en) *	2004-06-21	2014-10-08	Medarex, L.L.C.	Interferon alpha receptor i antibodies and their uses
JP5837730B2 (ja)	2005-02-10	2015-12-24	ベイラーリサーチインスティテュートＢａｙｌｏｒＲｅｓｅａｒｃｈＩｎｓｔｉｔｕｔｅ	抗インターフェロンアルファモノクローナル抗体及び使用方法
US7888481B2 (en) *	2005-02-10	2011-02-15	Baylor Research Institute	Anti-interferon alpha monoclonal antibodies and methods for use
JP2008543335A (ja) *	2005-06-22	2008-12-04	ジェネンテック・インコーポレーテッド	Ｉｆｎａｒ２を標的とするための方法と組成物
AU2009245792B2 (en) *	2008-05-07	2012-11-01	Coimmune, Inc.	Humanized antibodies against human interferon-alpha
FR2962651A1 (fr)	2010-07-15	2012-01-20	Oleg Iliich Epshtein	Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections fonctionnelles du tractus gastro-intestinal
FR2962656A1 (fr)	2010-07-15	2012-01-20	Oleg Iliich Epshtein	Procede pour augmenter l'effet d'une forme activee-potentialisee d'un anticorps
WO2018010140A1 (zh) *	2016-07-14	2018-01-18	中国科学院生物物理研究所	I型干扰素受体抗体及其用途
CN115558027B (zh) *	2022-12-05	2023-02-28	北京万泰生物药业股份有限公司	一种核酸酶的单克隆抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0563487A1 (en) *	1992-03-31	1993-10-06	Laboratoire Europeen De Biotechnologie S.A.	Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
IL108584A (en) *	1994-02-07	2008-03-20	Yeda Res & Dev	Cloning of the interferon-binding protein ALPHA / BETA
IL106591A (en) *	1992-09-03	2008-03-20	Yeda Res & Dev	Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
JPH11501283A (ja) *	1993-09-17	1999-02-02	ラボラトワールウーロペアンドゥバイオテクノロジソシエテアノニム	Ｉ型インターフェロンに対する中和活性を有する、インターフェロンレセプターに対するモノクローナル抗体を含んでなる医薬組成物

1996
- 1996-05-01 IL IL11809696A patent/IL118096A0/xx unknown
1997
- 1997-04-29 JP JP53837897A patent/JP4308322B2/ja not_active Expired - Lifetime
- 1997-04-29 BR BR9709202A patent/BR9709202A/pt active Search and Examination
- 1997-04-29 EP EP06014510A patent/EP1739177A1/en not_active Withdrawn
- 1997-04-29 DE DE69736835T patent/DE69736835T2/de not_active Expired - Lifetime
- 1997-04-29 WO PCT/IL1997/000138 patent/WO1997041229A1/en active IP Right Grant
- 1997-04-29 PT PT97919622T patent/PT927252E/pt unknown
- 1997-04-29 KR KR1020047011388A patent/KR100581798B1/ko not_active IP Right Cessation
- 1997-04-29 AU AU24027/97A patent/AU719995B2/en not_active Expired
- 1997-04-29 EA EA199800968A patent/EA002543B1/ru not_active IP Right Cessation
- 1997-04-29 DK DK97919622T patent/DK0927252T3/da active
- 1997-04-29 CN CNB971951861A patent/CN1198929C/zh not_active Expired - Lifetime
- 1997-04-29 EP EP97919622A patent/EP0927252B1/en not_active Expired - Lifetime
- 1997-04-29 IL IL126835A patent/IL126835A/en not_active IP Right Cessation
- 1997-04-29 CA CA2253239A patent/CA2253239C/en not_active Expired - Lifetime
- 1997-04-29 ES ES97919622T patent/ES2274542T3/es not_active Expired - Lifetime
- 1997-04-29 UA UA98116315A patent/UA76396C2/uk unknown
- 1997-04-29 AT AT97919622T patent/ATE342981T1/de active
- 1997-04-29 KR KR1019980708393A patent/KR20000064953A/ko active Search and Examination
1998
- 1998-04-29 US US09/171,979 patent/US6136309A/en not_active Expired - Lifetime
- 1998-10-29 NO NO19985050A patent/NO324206B1/no not_active IP Right Cessation
1999
- 1999-09-30 HK HK99104252A patent/HK1019339A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
BR9709202A (pt)	1999-08-10
DE69736835T2 (de)	2007-11-22
EA199800968A1 (ru)	1999-04-29
IL126835A (en)	2007-07-24
IL118096A0 (en)	1996-09-12
DK0927252T3 (da)	2007-02-05
EA002543B1 (ru)	2002-06-27
CN1198929C (zh)	2005-04-27
KR20000064953A (ko)	2000-11-06
JP4308322B2 (ja)	2009-08-05
ATE342981T1 (de)	2006-11-15
EP0927252B1 (en)	2006-10-18
DE69736835D1 (de)	2006-11-30
US6136309A (en)	2000-10-24
AU719995B2 (en)	2000-05-18
CA2253239A1 (en)	1997-11-06
HK1019339A1 (en)	2000-02-03
PT927252E (pt)	2007-01-31
KR100581798B1 (ko)	2006-05-25
WO1997041229A1 (en)	1997-11-06
ES2274542T3 (es)	2007-05-16
EP1739177A1 (en)	2007-01-03
KR20040075105A (ko)	2004-08-26
AU2402797A (en)	1997-11-19
JP2000509276A (ja)	2000-07-25
CA2253239C (en)	2010-08-10
EP0927252A1 (en)	1999-07-07
NO985050D0 (no)	1998-10-29
NO985050L (no)	1998-12-29
CN1220699A (zh)	1999-06-23
NO324206B1 (no)	2007-09-10

Publication	Publication Date	Title
UA76396C2 (en)	2006-08-15	Monoclonal antibody, which is able to be bound with receptor ifn -, block the biological activity of ifn- and ifn- and create higher antiviral titer against fn-, than against ifn- (variants), pharmaceutical composition for modulation or blocking biological activity of ifn-, hybridoma expressing denoted antibody (variants), and set for carrying out elisa-analysis of ifnab-bpi and/or ifnab-bpi
Tanaka et al.	1991	Molecular cloning and expression of a novel adhesion molecule, SC1
US7455977B2 (en)	2008-11-25	Methods of determining the level of human TBP-II with anti-TBP-II antibody
US6555111B2 (en)	2003-04-29	Method of inhibiting the cytocidal effect of TNF with TNF receptor-specific antibodies
UA75862C2 (uk)	2006-06-15	Виділений поліпептид, що зв'язується з il-18 (il-18bp) (варіанти), виділена молекула нуклеїнової кислоти, що його кодує (варіанти), антитіло, що зв'язується з даним поліпептидом, спосіб очищення il-18bp та композиція, що його містить
US20060247198A1 (en)	2006-11-02	TGF-beta type receptor cDNAs encoded products and uses therefor
CA2195868A1 (en)	1996-02-08	Antibodies which activate an erythropoietin receptor
IL106271A (en)	2008-03-20	Ligand to TNF 75P receptor and its preparation
US6458932B1 (en)	2002-10-01	Interferon-α/β binding protein, its preparation and use
AU688430B2 (en)	1998-03-12	Interferon-alpha/beta binding protein, its preparation and use
US5879896A (en)	1999-03-09	Method of screening for inhibitors of human thyrotropin releasing hormone (TRH) receptor
Hiraishi et al.	2003	Immunohistochemical distribution of human basigin by using a novel monoclonal antibody
WO1994009765A1 (en)	1994-05-11	Functional interactions between glial s-100b and central nervous system serotonergic neurons